|
Intraperitoneal hyperthermic chemoperfusion (IPHC) is a type of hyperthermia therapy used in combination with surgery in the treatment of advanced abdominal cancers. In this procedure, warmed anti-cancer drugs are infused and circulated in the peritoneal cavity (abdomen) for a short period of time. The chemotherapeutic agents generally infused during IPHC are mitomycin-C and cisplatin. IPHC is also called hyperthermic intraperitoneal chemotherapy (HIPEC), intra-abdominal hyperthermic chemoperfusion, intraoperative chemohyperthermic peritoneal perfusion (CHPP), or the Sugarbaker technique, after Paul Sugarbaker, developer and advocate of this procedure. ==Use== IPHC is generally used after surgical removal of as much cancer as possible (debulking), which may include the removal of all involved peritoneal areas. These procedures can be 8–10 hours long and carry a significant rate of complications. IPHC is used as a viable solution for certain advanced stage tumors in the abdomen that have spread many small tumors throughout the abdomen, when surgery is not likely to be possible or effective. It can also be applied, during surgery, directly on the area, for those whose abdominal cancer is advanced but is still considered surgically resectable, as an alternative to surgery and traditional chemotherapy alone.〔http://healthnews.uc.edu/news/?/22745/〕 The diseases most often treated with this method are cancer of the appendix, colorectal cancer, ovarian cancer, desmoplastic small round cell tumor and gastric cancer. It is also used for: * Mucinous Adenocarcinoma of Appendix * Mesothelioma * Low-Grade Sarcoma 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Intraperitoneal hyperthermic chemoperfusion」の詳細全文を読む スポンサード リンク
|